P&T
Our
Other
Journal
MediMedia Managed Markets

 

 

January 2014

If 1% of patients account for 21% of total health care spending, why is there so little proof of ROI from giving them appropriate care?

Joseph Burns

Bundled payments, big data, and advances in personalized medicine will change the way primary care physicians and others practice

Provider groups put money into systems that heighten the focus on measuring performance

Frank Diamond

Qsymia and Belviq can slow the progression of diabetes, but side effects and retail cost of about $200 per month are obstacles to formulary placement

Ed Silverman

Emerging data show impressive results on glycemic control, but what about long-term results, safety, and high maintenance costs?

Thomas Reinke
Angela K. Hochhalter, PhD ; Rashmita Basu, PhD ; Karim Prasla, PharmD ; Chanhee Jo, PhD



Departments
Legislation & Regulation

Consumers expect reasonable premiums and copayments but give health plans grief over a proven cost-control method. How soon we forget.

John Carroll
Medication Management

Management tactic borrowed from traditional pharmacy

Thomas Reinke
Tomorrow's Medicine

Twenty-five years ago we had not even identified the virus that was neither type A nor type B. Now we have slowed its spread and can cure it, at considerable cost.

Thomas Morrow, MD
The Formulary Files
Krishna Rutvij Patel